MindWalk Holdings (HYFT) Non Operating Income (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Non Operating Income of $12.4 for Q2 2026, up 688.26% year-over-year from $1.57 in Q2 2025, and down 99.94% quarter-over-quarter from $21617.1 in Q1 2026.
MindWalk Holdings (HYFT) Non Operating Income (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Non Operating Income for 4 consecutive years, with $12.4 the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income rose 688.26% year-over-year to $12.4; the TTM figure through Apr 2026 stood at -$3689.2 (up 98.3% YoY), while the FY2026 annual figure was $63467.0, up 129.87% from the prior year.
- Non Operating Income fell to $12.4 in Q2 2026 per HYFT's latest filing, from $21617.1 in the prior quarter.
- Across five years, Non Operating Income topped out at $21617.1 in Q1 2026 and bottomed at -$128910.1 in Q1 2025.
- Historically, Non Operating Income has averaged -$25399.5 across 4 years, with a median of -$2950.1 in 2024.
- Annual changes were most pronounced in 2025 — Non Operating Income plunged 5908.95% — and 2026, when it surged 688.26%.
- MindWalk Holdings' Non Operating Income stood at -$9587.4 in 2023, then sank by 793.65% to -$85677.8 in 2024, then soared by 70.45% to -$25316.5 in 2025, then jumped by 100.05% to $12.4 in 2026.
- Business Quant data shows HYFT's Non Operating Income at $12.4 in Q2 2026, $21617.1 in Q1 2026, and -$25316.5 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 12.40 |
| Jan 31, 2026 | 21,617.09 |
| Oct 31, 2025 | -25,316.55 |
| Apr 30, 2025 | -2.11 |
| Jan 31, 2025 | -128,910.11 |
| Oct 31, 2024 | -85,677.78 |
| Apr 30, 2024 | -2,950.08 |
| Jan 31, 2024 | 2,219.16 |
| Oct 31, 2023 | -9,587.42 |